A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

• ClinicalTrials.gov Identifier: NCT03134638
• Recruitment Status: Terminated
• First Posted: May 1, 2017
• Last Update Posted: March 9, 2021
• Sponsor: Syros Pharmaceuticals
• Information provided by (Responsible Party): Syros Pharmaceuticals

Tracking Information

• First Submitted Date: April 19, 2017
• First Posted Date: May 1, 2017
• Last Update Posted Date: March 9, 2021
• Actual Study Start Date: May 12, 2017
• Actual Primary Completion Date: May 15, 2020 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: September 9, 2019)

• (Part 1) First-cycle dose-limiting toxicities (DLTs) [ Time Frame: Within 1 year ]
• (Part 1) ECG QTc Interval [ Time Frame: Within 1 year ]
• (Part 1 and 2) Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Within 1 year ]

Original Primary Outcome Measures (submitted: April 25, 2017)

• First-cycle dose-limiting toxicities (DLTs) [ Time Frame: Up to 1 year ]
• Maximum tolerated dose (MTD) [ Time Frame: Up to 1 year ]

Current Secondary Outcome Measures (submitted: September 9, 2019)

• Peak Plasma Concentration (Cmax) of SY-1365 as a single agent (Part 1 and 2) and in combination with carboplatin (Part 2 only) [ Time Frame: Within 1 year ]
• Area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-last) of SY-1365 as a single agent (Part 1 and 2) and in combination with carboplatin (Part 2 only) [ Time Frame: Within 1 year ]
• Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-INF) of SY-1365 as a single agent (Part 1 and 2) and in combination with carboplatin (Part 2 only) [ Time Frame: Within 1 year ]
• (Part 1 and 2) Terminal elimination half life (t1/2) [ Time Frame: Within 1 year ]
• (Part 1 and 2) Evaluate the PD effects of SY-1365 as a single agent (Part 1 and 2) and in combination with carboplatin or fulvestrant (Part 2 only) [ Time Frame: Within 1 year ]
  Done by measuring the CDK7 occupancy in PBMCs and tumor tissue after single agent or combination administration
• (Part 2) Evaluation of Objective Response Rate (ORR) in patients with ovarian cancer, breast cancer, and advanced solid tumors as measured by RECIST v1.1 [ Time Frame: Within 1 year ]
• (Part 2) Evaluation of Duration of Response (DoR) in patients with ovarian cancer, breast cancer, and advanced solid tumors as measured by RECIST v1.1 [ Time Frame: Within 1 year ]
• (Part 2) Evaluation of Disease Control Rate (DCR) in patients with ovarian cancer, breast cancer, and advanced solid tumors as measured by RECIST v1.1 [ Time Frame: Within 1 year ]

Original Secondary Outcome Measures (submitted: April 25, 2017)

• Peak plasma concentration (Cmax) [ Time Frame: Up to 4 months ]
• Area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-last) [ Time Frame: Up to 4 months ]
• Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-INF) [ Time Frame: Up to 4 months ]
• Terminal elimination half-life (t1/2) [ Time Frame: Up to 4 months ]
• Time of maximum observed plasma concentration (tmax) [ Time Frame: Up to 4 months ]
• Evaluate the PD effects of SY-1365 by measuring the CDK7 occupancy after SY-1365 administration in PBMCs and tumor tissue [ Time Frame: Up to 1 year ]
• Evaluate the antitumor activity of SY-1365 in patients with select advanced solid tumor malignancies, including SCLC, TNBC, and ovarian cancer [ Time Frame: Up to 1 year ]
  Clinical activity of SY-1365 as measured by RECIST 1.1 response criteria including the Objective Response Rate (ORR) and duration of response (DoR)

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
• Official Title: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors

Brief Summary

This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2.

Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with select solid tumors, and to confirm target engagement and downstream pathway impact in patients with any solid tumor histology.

Detailed Description

This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to identify a dose and regimen for further evaluation in Part 2. SY-1365 will be administered intravenously weekly & twice weekly for 3 weeks of each 4 week cycle. Dose escalation will proceed until the determination of the maximum tolerated dose (MTD) or a recommended dose and regimen for evaluation in Part 2 of the study. Part 1 was concluded in September 2018 with a total of 32 evaluable patients.

Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with select solid tumors, and to confirm target engagement and downstream pathway impact in patients with any solid tumor histology.

Preliminary anti-tumor activity will be evaluated in up to approximately 102 evaluable patients in Part 2, with SY-1365 administered alone, in combination with carboplatin, or in combination with fulvestrant. Part 2 will consist of five cohorts:

• Cohort 1: approximately 24 patients with advanced ovarian cancer with 3+ previous lines of treatment. Monotherapy
• Cohort 2: approximately 24 patients with relapsed ovarian cancer with previous platinum therapy. SY-1365 + Carboplatin
• Cohort 3: approximately 12 patients with clear cell ovarian cancer. Monotherapy
• Cohort 4: approximately 20-30 patients with biopsy-accessible, advanced solid tumors of any histology. Monotherapy.
• Cohort 5: approximately 12 patients with HR+ metastatic breast cancer post CDK4/6 + hormonal therapy treatment. SY-1365 + fulvestrant.

Overall, the study may enroll up to approximately 137 evaluable patients across dose escalation (Part 1) and expansion cohorts (Part 2, Cohorts 1, 2, 3, 4, and 5).

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: Non-Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Advanced Solid Tumors
• Ovarian Cancer
• Breast Cancer

Intervention

• Drug: SY-1365 (Part 1)

  Two dosing schedules will be evaluated in dose escalation and a dose(s)/schedule(s) will be determined for Part 2:

  • Twice weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle.
  • Weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28 day) cycle.
• Drug: Carboplatin
  Carboplatin will be administered on Day 1 of each 3 week (21-day) cycle (Part 2 only)
  Other Name: paraplatin
• Drug: Fulvestrant
  Fulvestrant will be administered as an intramuscular (IM) dose of 500 mg every 2 weeks for the first 3 doses on Day 1 and Day 15 of the first 28-day cycle (Cycle 1), and on Day 1 of the second 28 day cycle (Cycle 2), and monthly thereafter starting on Day 1 of Cycle 3 (Part 2 only)
  Other Name: faslodex
• Drug: SY-1365 (Cohort 2)
  In combination with carboplatin, SY-1365 will be administered by intravenous infusion over 1 or 2 hours for 2 weeks of each 3 week (21-day) cycle (Part 2 only)
• Drug: SY-1365 (Cohort 5)
  In combination with fulvestrant, SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28-day) cycle (Part 2 only)
• Drug: SY-1365 (Part 2 Single Agent)
  SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle

Study Arms

• Experimental: Dose Escalation
  Dose escalation phase to explore maximum tolerated dose across two dosing schedules. SY-1365 will be administered intravenously weekly and twice-weekly for 3 weeks of each 4-week cycle
  Intervention: Drug: SY-1365 (Part 1)
• Experimental: Advanced Ovarian Cancer
  Patients with ovarian cancer previously treated with ≥ 3 prior lines of therapy (SY-1365 single agent)
  Intervention: Drug: SY-1365 (Part 2 Single Agent)
• Experimental: Relapsed Ovarian Cancer
  Patients with ovarian cancer previously treated with ≥ 1 prior line of therapy including a platinum-based regimen (SY-1365 + carboplatin)
  Interventions:

  • Drug: Carboplatin
  • Drug: SY-1365 (Cohort 2)
• Experimental: Clear Cell Ovarian Cancer
  Patients with clear cell ovarian cancer previously treated with ≥ 1 prior line of therapy (SY-1365 single agent)
  Intervention: Drug: SY-1365 (Part 2 Single Agent)
• Experimental: Advanced Solid Tumors
  Biopsy cohort of approximately 20-30 patients with advanced solid tumors from whom pre- and post-treatment biopsies will be obtained (SY-1365 single agent)
  Intervention: Drug: SY-1365 (Part 2 Single Agent)
• Experimental: HR+ breast cancer
  Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy (SY-1365 + fulvestrant)
  Interventions:

  • Drug: Fulvestrant
  • Drug: SY-1365 (Cohort 5)

• Publications *: Sava GP, Fan H, Coombes RC, Buluwela L, Ali S. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823. doi: 10.1007/s10555-020-09885-8.

Recruitment Information

• Recruitment Status: Terminated
• Actual Enrollment (submitted: March 5, 2021): 107
• Original Estimated Enrollment (submitted: April 25, 2017): 70
• Actual Study Completion Date: June 24, 2020
• Actual Primary Completion Date: May 15, 2020 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• 18 years of age or older

• Disease status

  • Part 1: any histologically-confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective
  • Part 2, Cohorts 1 and 2, all patients must have a histologically-confirmed diagnosis of high grade serous ovarian cancer (including fallopian tube cancer and/or primary peritoneal cancer)
  • Part 2, Cohort 1, patients must have received ≥ 3 prior treatment regimens for ovarian cancer including a platinum-based regimen. Patients whose ovarian cancer harbors a mutation in breast cancer gene (BRCA), either germline or somatic, must have been previously treated with a poly(ADP ribose) polymerase (PARP) inhibitor, or be considered unwilling or ineligible for treatment with a PARP inhibitor
  • Part 2, Cohort 2, patients must have received ≥ 1 prior treatment regimen for ovarian cancer, at least 1 of which is a platinum-based regimen
  • Part 2,Cohort 3, all patients must have a histologically-confirmed diagnosis of clear cell ovarian cancer and must have received ≥ 1 prior treatment regimen for clear cell ovarian cancer, at least 1 of which is a platinum-based regimen.
  • Part 2, Cohort 4, any histologically-confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective. Must have accessible tumor tissue and be willing to undergo tumor tissue sampling (biopsies/aspirates) pre-, during, and post-treatment
  • Part 2, Cohort 5, postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer who have failed prior treatment with a CDK 4/6 inhibitor in combination with a hormonal therapy (i.e. aromatase inhibitors, fulvestrant). Treatment failure is based on development of clinical or documented progression during treatment with a CDK4/6 inhibitor in combination with hormonal therapy after ≥ 6 months of therapy. Progression following discontinuation of CDK4/6 treatment due to safety and/or tolerability is not considered as treatment failure for purposes of inclusion criteria. Documentation of HR-positive and HER2-negative status must be available.
• At least 1 measurable lesion by RECIST 1.1
• All toxicities (except alopecia) from prior cancer treatments must have resolved to ≤ Grade 1 or returned to baseline levels prior to enrollment
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Life expectancy > 3 months
• Absolute neutrophil count: ≥ 1.5 x 10^9/L
• Platelets: ≥ 100 x 10^9/L
• Hemoglobin: ≥ 9 g/dL
• Total bilirubin ≤ 1.5 x institutional upper limit of normal [ULN]
• AST (SGOT)/ ALT (SGPT): ≤ 3.0 x institutional ULN
• Creatinine ≤ 1.5 x institutional ULN OR creatinine clearance ≥ 60 mL/min by Crockoft-Gault for participants with creatinine levels above institutional normal
• Negative serum pregnancy test for women of child bearing potential

Exclusion Criteria:

• Chemotherapy or limited field radiotherapy within 2 weeks, wide field radiotherapy within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks prior to entering the study
• Major surgery within 2 weeks of starting the study treatment, or not recovered to baseline status from the effects of surgery received > 2 weeks prior
• Received any other investigational agents within 4 weeks prior to enrollment, or < 5 half-lives since completion of previous investigational therapy, whichever is shorter
• Received previous non-cytotoxic, FDA-approved anticancer agent within previous 2 weeks, or < 5 half-lives since completion of previous therapy, whichever is shorter
• Prior exposure to transcriptional kinase family CDK inhibitors, such as the CDK7 and CDK9 inhibitors alvocidib (Flavopiridol), dinaciclib, and seliciclib. Exception: previous exposure to cell cycle CDK inhibitors such as CDK4 and CDK6 (eg, palbociclib) is allowed
• Known brain metastases or carcinomatous meningitis. Exception: previously treated brain metastatic disease that remains stable on MRI ≥ 4 weeks prior to enrollment without steroids or anti-epileptic medications
• History of allergic reactions attributed to compounds of similar chemical composition to SY-1365
• Immunocompromised patients with increased risk of opportunistic infections, including known HIV-positive patients
• Patients with known active Hepatitis B or Hepatitis C infection
• Prior treatment (< 2 weeks before start of SY-1365) with moderate or strong CYP3A4 inducers or strong CYP3A4 inhibitors
• Baseline QT interval corrected with Fridericia's method (QTcF) > 480 ms. NOTE: criterion does not apply to patients with a right or left bundle branch block (QTc interval)
• Significant cardiac risk, including: History of clinically significant cardiac disease or clinically relevant uncontrolled cardiac risk factors
• Uncontrolled intercurrent illness

Part 2 Only:

• Cohorts 1 and 2: Patients with low-grade ovarian cancer (eg, low grade serous, mucinous carcinoma) are not eligible
• Cohort 2: Prior adverse reaction(s) to carboplatin or any medical condition that precludes re-treatment with carboplatin
• Cohort 5: More than 1 prior line of treatment with systemic chemotherapy for advanced/metastatic disease; Advanced/metastatic disease that is symptomatic and/or with visceral spread that are at risk of life-threatening complications in the short term; Contraindication to receiving fulvestrant OR any medical condition that requires a lower dose of fulvestrant at the initiation of therapy

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada, France, United States

Administrative Information

• NCT Number: NCT03134638
• Other Study ID Numbers: SY-1365-101
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: Undecided

• Current Responsible Party: Syros Pharmaceuticals
• Original Responsible Party: Same as current
• Current Study Sponsor: Syros Pharmaceuticals
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Kate Madigan, MD; Syros Pharmaceuticals

• PRS Account: Syros Pharmaceuticals
• Verification Date: November 2019